The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech
Stock and Other Ownership Interests - Roche
Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.
 
Mark A. Socinski
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Genentech; Guardant Health; Lilly; Merck; Roche/Genentech
Consulting or Advisory Role - AstraZeneca/MedImmune; Genentech; Janssen; Lilly; Novartis
Speakers' Bureau - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Genentech (Inst); Spectrum Pharmaceuticals (Inst)
 
Robert M. Jotte
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Consulting or Advisory Role - Mirati Therapeutics
Speakers' Bureau - Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech
 
Federico Cappuzzo
Honoraria - AstraZeneca/MedImmune; Lilly; MSD Oncology; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; MSD Oncology; pfizer; Roche/Genentech; Takeda
 
Makoto Nishio
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AbbVie; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Teijin Pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tony S. K. Mok
Employment - The Chinese University of Hong Kong
Leadership - AstraZeneca; Aurora Tele-Oncology Platform; Hutchison China Meditech; Sanomics Limited
Stock and Other Ownership Interests - Aurora Tele-Oncology Platform; Hutchison China Meditech; Sanomics Limited
Honoraria - ACEA Pharmaceutical Research; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Fishawack Facilitate; InMed; Lilly; Merck Sharp & Dohme; Novartis; Origimed; Pfizer; Prime Oncology; Roche; Sanofi Aventis GmbH; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; ACEA Pharmaceutical Research; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; BeiGene; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; CStone Pharmaceuticals; Curio Science; Daiichi Sankyo/UCB Japan; Eisai; Fishawack Facilitate; Gritstone Bio; Guardant Health; Hengrui Therapeutics; Ignyta; Incyte; Inivata; IQvia; Lilly; Loxo; Lunit; Merck Serono; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Pfizer; Puma Biotechnology; Roche; SFJ Pharmaceuticals Group; Takeda; Vertex; Yuhan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Takeda (Inst); Xcovery (Inst)
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Gene Grant Finley
Stock and Other Ownership Interests - Proteostasis Therapeutics
Consulting or Advisory Role - Bayer; Merck; Secura Bio
Research Funding - AstraZeneca (Inst); BeyondSpring Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Wei Yu
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Hina Patel
Stock and Other Ownership Interests - Roche/Genentech
 
Nindhana Paranthaman
Employment - Genentech
 
Ilze Bara
No Relationships to Disclose
 
Howard West
Honoraria - AstraZeneca; Genentech/Roche; Merck; Takeda
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Merck; Takeda
Speakers' Bureau - AstraZeneca; Merck; Takeda